Dual Task Perturbation Training for OAwMCI
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jun 23, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new training method to help older adults with Mild Cognitive Impairment (MCI) improve their balance and reduce the risk of falls. Researchers have found that older adults with MCI often have difficulties with balance and walking, especially when they are trying to think or focus on something else at the same time. The study aims to test a special treadmill that creates safe balance challenges while participants walk, combined with exercises that also engage their thinking skills. This approach is hoped to enhance their ability to respond to unexpected balance disruptions and improve overall physical activity.
To take part in this study, participants must be over 55 years old, have been diagnosed with MCI (scoring less than 26 out of 30 on a cognitive test), and be able to walk at least 10 meters without any aids. They should not have any serious health issues or recent surgeries that could affect their ability to participate. If eligible, participants can expect to engage in a series of training sessions that will focus on improving their balance and cognitive function in a supportive environment. This trial is a promising step towards finding effective ways to help older adults maintain their independence and reduce the risk of falls.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age group: Older adults between the age group \> 55 years old with MOCA less than 26 out of 30 will be classified as mild cognitive impairment and those above 26 out of 30 as cognitively intact older adults .
- • Absence of any acute or chronic neurological (Stroke, Parkinson's disease, Alzheimer's disease), cardiopulmonary, musculoskeletal, or systemic diagnosis.
- • No recent major surgery (\< 6 months) or hospitalization (\< 3 months)
- • Not on any sedative drugs
- • Can understand and communicate in English
- • Ability to walk more than 10 meters without an assistive device
- Exclusion Criteria:
- • Participants will not proceed with the study if any of the following occurs at baseline measurement: 1) HR \> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \> 165 mmHg and/or diastolic blood pressure (DBP) \> 110 mmHg during resting), and/or 3) oxygen saturation (measured by pulse oximeter) during resting \< 90%.
- • History of bone fracture or significant other systemic disease or surgery in the last six months
- • Specific to MRI participants: Self-reported presence of a pacemaker, metal implants other than orthopedic implants, and/or Claustrophobia, cataract surgery (lens not compatible to the MRI confirmed by the MRI technician)
- • Weighs \> 220 lbs (Harness weight threshold)
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Tanvi Bhatt
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials